SR
SRT.F Sartorius Aktiengesellschaft
- Market cap
- EUR 15.8B
- P/E
- 72.6x
- P/B
- 5.36x
- ROE
- 6.9%
- Dividend yield
- 0.32%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SRT.F undervalued?
Graham numberThe Graham number of Sartorius Aktiengesellschaft cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sartorius Aktiengesellschaft fundamental analysis
No fundamental analysis for Sartorius Aktiengesellschaft yet.
Sartorius Aktiengesellschaft stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supp…
Full company profileSartorius Aktiengesellschaft financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sartorius Aktiengesellschaft annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.30B | 1.40B | 1.57B | 1.83B | 2.34B | 3.45B | 4.17B | 3.40B | 3.38B | 3.54B | 3.65B |
| Gross Profit | 632M | 707M | 804M | 941M | 1.21B | 1.84B | 2.20B | 1.57B | 1.52B | 1.64B | 1.69B |
| Operating Income | 248M | 261M | 299M | 362M | 511M | 933M | 1.18B | 544M | 437M | 569M | 645M |
| EBITDA | - | 312M | 399M | 452M | 650M | 927M | 1.50B | 873M | 787M | 931M | 1.13B |
| Net Income | 103M | 115M | 141M | 157M | 226M | 319M | 678M | 206M | 84.0M | 155M | 201M |
| EPS | - | 1.68 | 2.07 | 2.29 | 3.31 | 4.66 | 9.91 | 3.01 | 1.22 | 2.24 | 2.92 |
| Balance Sheet | |||||||||||
| Total Assets | 1.75B | 2.30B | 2.53B | 2.84B | 4.70B | 5.70B | 6.98B | 9.75B | 10.1B | 9.72B | 9.67B |
| Total Liabilities | 1.02B | 1.49B | 1.55B | 1.76B | 3.30B | 3.98B | 4.32B | 6.99B | 6.21B | 5.85B | 5.53B |
| Shareholders' Equity | 580M | 618M | 741M | 810M | 1.05B | 1.26B | 1.99B | 2.07B | 2.76B | 2.71B | 2.93B |
| Cash & Short-term Investments | 62.0M | 59.4M | 45.2M | 53.9M | 203M | 343M | 166M | 379M | 813M | 541M | 231M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 170M | 207M | 245M | 377M | 512M | 873M | 734M | 821M | 976M | 837M | 749M |
| Capital Expenditure | 149M | 197M | 233M | 226M | 240M | 407M | 523M | 606M | 410M | 442M | 349M |
| Free Cash Flow | - | 9.41M | 11.3M | 152M | 271M | 459M | 212M | 216M | 566M | 395M | 399M |
| Ratios | |||||||||||
| ROE | 17.8% | 18.6% | 19.1% | 19.3% | 21.6% | 25.3% | 34.1% | 9.9% | 3.0% | 5.7% | 6.9% |
| ROA | 5.9% | 5.0% | 5.6% | 5.5% | 4.8% | 5.6% | 9.7% | 2.1% | 0.8% | 1.6% | 2.1% |
| Net Profit Margin | 7.9% | 8.2% | 9.0% | 8.6% | 9.7% | 9.2% | 16.2% | 6.1% | 2.5% | 4.4% | 5.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sartorius Aktiengesellschaft dividends
- Dividend yield
- 0.32%
- Forward dividend
- 0.73 EUR
- Payout ratio
- 32.8%
- Ex-dividend date
- Mar 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 50.8M | 0.74 | 32.8% |
| 2024 | EUR 50.7M | 0.73 | 60.4% |
| 2023 | EUR 98.2M | 1.44 | 47.8% |
| 2022 | EUR 85.9M | 1.26 | 12.7% |
| 2021 | EUR 48.2M | 0.70 | 15.1% |
| 2020 | EUR 24.3M | 0.35 | 10.7% |
| 2019 | EUR 42.1M | 0.62 | 26.8% |
| 2018 | EUR 34.5M | 0.50 | 24.4% |
| 2017 | EUR 31.1M | 0.45 | 27.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Jun 13, 2016.
Who owns Sartorius Aktiengesellschaft
- Insiders 87.07%
- Institutions 1.21%
- Public & others 11.72%
- Shares outstanding 34.2M
- Free float 27.5M
Sartorius Aktiengesellschaft company profile
- Company name
- Sartorius Aktiengesellschaft
- Ticker
- SRT.F
- ISIN
- DE0007165607
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 14,273
- Fiscal year end
- December
- Address
- Otto-Brenner-Strasse 20, Göttingen, Germany, 37079
- Phone
- 49 551 308 0
- Website
- sartorius.com
About Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions. The company serves the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
Sartorius Aktiengesellschaft management
9- Dr. Michael GrosseCEO & Chairman of the Executive Board · born 1967
- Dr. Florian Funck Dipl.Kfm.CFO & Member of Executive Board · born 1971
- Dr. Rene FaberHead of Bioprocess Solutions Division & Member of Executive Board · born 1975
- Dr. Alexandra GatzemeyerHead of the Lab Products & Services Division and Member of Executive Board · born 1979
- Ms. Patricia SpannagelHead of Quality Assurance - Mechatronics Division Goettingen
- Ralf MohrschladtPhysicist & Head of Supply Chain Management - Germany
- Ms. Petra MullerHead of Investor Relations
- Mr. Maurice PhelanPresident of Sartorius North America
- Dr. Theo ThijssenPresident of Environmental Technology Division